Freehold Surgical

Executive Summary

Freehold Surgical, founded in 2018 and based in Freehold, New Jersey, is a private medical device company specializing in innovative, hands-free surgical retractors for minimally invasive procedures. Its flagship products, the FreeHold Duo and Trio Retractors, are fully adjustable, completely intracorporeal devices designed to optimize visualization and improve surgical autonomy in laparoscopic and robotic surgeries. By minimizing incisions and eliminating the need for manual retraction or additional ports, the technology enhances patient outcomes and streamlines operating room efficiency. The company addresses a significant unmet need in the rapidly growing minimally invasive surgery market, valued at over $20 billion. Despite being in the early commercialization stage with no disclosed funding rounds or revenue, Freehold Surgical represents a compelling opportunity for investors seeking disruptive medical technologies. The company's focus on improving surgical workflow and patient recovery aligns with broader trends toward value-based care and outpatient procedures. With its differentiated product design and strong intellectual property potential, Freehold Surgical is well-positioned to capture market share from traditional retractor systems and establish partnerships with leading surgical robotics platforms. Key risks include regulatory clearance timelines and competitive pressures from established players. Overall, the company's innovative approach and market potential support a moderate conviction rating.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Duo and Trio Retractors70% success
• H2 2026Strategic Partnership with Robotic Surgery Platform (e.g., Intuitive Surgical, Medtronic)50% success
• Q1 2027First Commercial Sales and Initial Clinical Adoption60% success